AOD-9604 Compounding Pharmacy: Research-Only vs Medical-Grade Peptides Explained

What AOD-9604 Actually Is

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176-191 of the hGH C-terminal region. Researchers at Monash University first isolated this fragment in the 1990s and showed it retained the lipolytic activity of full-length hGH without detectable binding to the IGF-1 receptor. That receptor selectivity made it attractive for obesity research. Heffernan et al. Studied related GH fragment pharmacology and published findings accessible via PubMed.

The peptide reached Phase II and Phase III clinical trials under the brand name Tregopil... No, AOD-9604 itself was studied under the name "AOD9604" by Metabolic Pharmaceuticals in trials including a 24-week, placebo-controlled study in 300 obese adults. That trial reported modest, non-statistically significant weight reductions versus placebo, and the FDA did not approve an NDA. The trial design is summarized in the ClinicalTrials registry.

Why the FDA Never Approved AOD-9604

The Phase III program failed to meet its primary endpoint. Without approval, AOD-9604 cannot be legally marketed as a finished drug product in the United States. Compounding pharmacies may still prepare it under specific legal authority, but that authority has boundaries most buyers do not understand.

Mechanism in Brief

AOD-9604 stimulates lipolysis through beta-3 adrenergic receptor pathways and may inhibit lipogenesis, according to preclinical rodent data. A 2001 paper in the American Journal of Physiology demonstrated these effects in obese Zucker rats. Translating rodent lipolysis data to human clinical outcomes has proved far more difficult, which is why the Phase III results disappointed sponsors.

The Legal Framework Governing AOD-9604 in the United States

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed pharmacies to compound drugs for individual patients when a licensed prescriber writes a valid prescription. The pharmacy must use bulk drug substances that appear on an FDA-reviewed list or, for substances not yet on that list, meet criteria the FDA has not yet evaluated as bulk candidates. FDA guidance on 503A bulk drug substances is published at FDA.gov.

AOD-9604 is not currently on the 503A Bulks List nor on the Category 1 (nominated, under evaluation) or Category 2 (nominated, not under evaluation) lists with a positive outcome. This places compounding pharmacies preparing AOD-9604 in a legally contested position. Prescribers and patients should review the current FDA bulks list status before initiating therapy. The FDA's regularly updated 503A nominations table is available here.

503B Outsourcing Facilities

Section 503B facilities compound larger batches without patient-specific prescriptions but must register with the FDA and comply with Current Good Manufacturing Practice (cGMP) standards. They face more rigorous inspection schedules than 503A pharmacies. FDA oversight of 503B outsourcing facilities is described in the agency's compounding guidance documents.

The Drug Supply Chain Security Act

The DSCSA, enacted in 2013 and now fully phased in, requires dispensers and trading partners to track and trace prescription drug products through the supply chain. Compounded drugs from 503A pharmacies dispensed directly to patients are exempt from certain DSCSA serialization requirements, but the underlying ingredients must still originate from FDA-registered facilities. Full DSCSA requirements are outlined at FDA.gov. Research-grade chemical suppliers operate entirely outside this framework.

USP <797> and USP <795>: What the Standards Actually Require

USP <797> for Sterile Preparations

USP <797> is the compendial standard governing sterile compounding. For a subcutaneously injected peptide like AOD-9604, compliance requires ISO 5 primary engineering controls (laminar flow hoods or isolators), environmental monitoring, personnel garbing and glove-fingertip sampling, sterility testing for batches released beyond immediate use, and endotoxin testing. The United States Pharmacopeia publishes USP <797> requirements, with a 2023 revision taking effect November 1, 2023.

The endotoxin limit for non-intrathecal injected preparations is calculated per the formula: endotoxin limit (EU/kg/hr) = K/M, where K = 5 EU/kg/hr for non-pyrogenic routes and M = the maximum dose in mL/kg/hr. Most subcutaneous peptide vials must test below 14.29 EU/mL under this formula. Research-grade suppliers are not required to perform this test at all.

USP <795> for Non-Sterile Preparations

USP <795> governs non-sterile compounding such as oral capsules or topical creams. Oral or sublingual AOD-9604 formulations fall under <795>. The bioavailability of oral peptides this short is thought to be very low given gastrointestinal proteolysis, though no published human pharmacokinetic study for oral AOD-9604 exists in peer-reviewed literature as of this writing.

HPLC Purity Testing

High-performance liquid chromatography (HPLC) is the standard analytical method for confirming peptide identity and purity. Reputable compounding pharmacies producing injectable peptides target ≥ 98% purity by HPLC. Analytical methods for synthetic peptide purity are described in the context of pharmaceutical quality by FDA guidance documents on compounding quality. Research-grade suppliers often report 95% purity or disclose no purity data at all.

Research-Grade vs Medical-Grade: A Direct Comparison

The table below reflects the regulatory and quality differences that a clinician or informed patient should understand before sourcing AOD-9604.

| Feature | Research-Grade ("for lab use only") | Medical-Grade (503A/503B Compounded) | |---|---|---| | Prescription required | No | Yes | | Sterility testing | Not required | Required by USP <797> | | Endotoxin testing | Not required | Required by USP <797> | | HPLC purity target | Varies (often undisclosed) | ≥ 98% at reputable pharmacies | | FDA oversight | None for the final product | 503A: state board + FDA; 503B: FDA cGMP | | Labeling requirements | None for human-use claims | Full Rx labeling with lot, expiry, BUD | | Legal status for human use | Not lawful for human administration | Lawful with valid Rx under 503A authority | | PCAB accreditation possible | No | Yes |

Purchasing from a "research chemical" vendor and self-administering is not equivalent to receiving a compounded prescription peptide. The two categories differ at every layer: legal, manufacturing, analytical, and clinical.

FDA Warning Letters Targeting Research Peptide Vendors

The FDA has issued warning letters to companies selling peptides labeled "research use only" when those companies made implicit or explicit human-use claims, provided dosing instructions, or sold products in formats clearly intended for injection by people. One example is the FDA's 2022 warning letter to a peptide vendor for illegally marketing unapproved drugs. These letters cite violations of sections 505(a) and 502(f)(1) of the FD&C Act. Receiving a warning letter does not automatically close the vendor, so buyers cannot rely on "still operating" as a quality signal.

PCAB Accreditation and What It Adds

The Pharmacy Compounding Accreditation Board (PCAB), now administered under ACHC, accredits compounding pharmacies that voluntarily submit to unannounced inspections, facility audits, and quality-management reviews that exceed most state board minimums. A PCAB-accredited pharmacy must maintain documented standard operating procedures for every sterile preparation, including peptides. ACHC-PCAB accreditation standards are described at the ACHC website, which cross-references USP standards.

PCAB accreditation is not a guarantee of clinical efficacy for any peptide. What it does guarantee is a higher probability that the product you receive was made in a documented, audited environment using tested starting materials. For a peptide with AOD-9604's regulatory ambiguity, that manufacturing assurance may be the most concrete quality signal available to a prescriber.

How to Verify PCAB Status

A pharmacy claiming PCAB accreditation can be verified directly through the ACHC accreditation lookup tool. State pharmacy board licensure can be verified through the National Association of Boards of Pharmacy (NABP) at nabp.pharmacy. Both checks take under two minutes and cost nothing.

Practical Buyer Guidance for Clinicians and Patients

What a Legitimate Prescription Pathway Looks Like

A patient receiving AOD-9604 through a lawful channel will go through a telehealth or in-person consultation, receive a diagnosis-linked prescription, and have that prescription sent directly from the prescribing practice to a licensed compounding pharmacy. The pharmacy ships the product in tamper-evident packaging with a pharmacy label listing the patient name, prescriber name, lot number, beyond-use date (BUD), concentration, and storage instructions. No legitimate compounding pharmacy sells injectable peptides directly to consumers without a prescription on file. FDA's overview of how compounding differs from manufacturing explains these expectations.

Questions to Ask Any Compounding Pharmacy

Before a prescriber sends a peptide order to a pharmacy, or before a patient fills one, the following questions are worth asking directly:

• Does the pharmacy hold PCAB accreditation, and can they provide the accreditation certificate number?
• Is AOD-9604 prepared in an ISO 5 cleanroom with documented environmental monitoring logs?
• Will they provide a certificate of analysis (COA) showing HPLC purity and endotoxin results for the specific lot dispensed?
• Where does the API (active pharmaceutical ingredient) originate, and is the supplier FDA-registered?

A pharmacy unwilling to answer these questions should not receive a compounded peptide order. Period.

Red Flags in the Research-Grade Market

Research-grade vendors operating websites that feature dosing calculators, before-and-after photos, or "reconstitution guides" are marketing for human use while hiding behind a "not for human use" disclaimer. That disclaimer provides no legal protection to the buyer and is typically added to sidestep FDA jurisdiction, not to inform researchers. FDA has explained this regulatory evasion tactic in its guidance on internet sales of unapproved drugs.

Bacterial endotoxins in improperly manufactured injectable peptides cause fever, rigors, and in severe cases septic shock. A 2020 review in the journal Frontiers in Pharmacology examining peptide therapy safety noted that endotoxin contamination represents the primary adverse event risk in non-pharmaceutical-grade peptide preparations. Related safety considerations for peptide-based therapeutics are discussed in the published literature.

AOD-9604 Quality Testing: What the Certificate of Analysis Should Show

A valid COA from a compounding pharmacy or a pharmaceutical-grade API supplier should include all of the following:

• Peptide identity: confirmed by mass spectrometry or amino acid analysis
• HPLC purity: expressed as a percentage of the main peak area; target ≥ 98%
• Water content: Karl Fischer titration result (relevant to lyophilized peptides)
• Endotoxin: bacterial endotoxin test (BET) result in EU/mg or EU/mL with the pass/fail limit stated
• Sterility: sterility test result (USP <71>) for injectable preparations
• Appearance: description of the reconstituted solution
• Lot number and expiration date: traceable to the specific batch

A COA lacking endotoxin and sterility data for an injectable preparation is not a COA in any clinically meaningful sense. It is an identity document, nothing more.

Mass Spectrometry as Identity Confirmation

HPLC purity can be high while the compound is still incorrect. A peptide with the right molecular weight distribution but a single amino acid substitution will produce a near-identical HPLC chromatogram. Mass spectrometry confirms the molecular mass and, with tandem MS, the amino acid sequence. Methods for peptide characterization by mass spectrometry are covered in FDA guidance on analytical procedures for drug substances. Pharmacies producing peptides for clinical use should be able to provide MS confirmation data, at least at the API level.

The Regulatory Outlook for Compounded Peptides in 2025

The FDA's approach to compounded peptides has tightened since 2023. Several peptides, including BPC-157 and TB-500, have been moved to the Category 2 "do not compound" list following FDA evaluation. AOD-9604 has not yet been placed on a positive bulks list. The FDA updates the 503A bulks nomination status regularly on its compounding webpage.

Prescribers operating peptide-based practices should monitor the FDA bulks list quarterly. A peptide that is lawful to compound today may shift to a restricted or prohibited status within a single regulatory cycle. That is not hypothetical. It happened with BPC-157 in 2024, and the same process applies to AOD-9604.

State medical boards have also increased scrutiny of peptide prescribing. At least four states issued guidance between 2023 and 2025 requiring that compounded peptide prescriptions include documented clinical rationale in the patient record. Prescribers should maintain detailed SOAP notes for any AOD-9604 prescription, including the diagnosis code, the rationale for choosing a compounded peptide, and the monitoring plan.